Investor Alert

Market Pulse Archives

Oct. 30, 2020, 1:04 p.m. EDT

Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data, stock suffering record plunge

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Bellicum Pharmaceuticals Inc. (BLCM)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Bellicum Pharmaceuticals Inc. /zigman2/quotes/202566367/composite BLCM +2.50% plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company said it was slashing its workforce by 79% as part of a restructuring, following disappointing data from a trial of its pancreatic cancer treatment. The interim trial results of BPX-601 were "encouraging" in terms of safety and GoCAR-T cell activation, but clinically meaningful efficacy was not observed. "We have concluded that Bellicum must reduce spending on preclinical programs and shift its resources to enable achievement of meaningful milestones in the clinic," said Chief Executive Rick Fair. The company said it was cutting its staff to 14 employees from 68 by the end of 2020. Ladenburg Thalmann analyst Wangzhi Li followed by downgrading Bellicum to neutral from buy, writing in a note to clients that the interim trial results "raises questions on a key intended function of GoCART technology and significantly increases uncertainty on its outlook." The stock has tumbled 70.3% year to date, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB +3.92% has gained 8.1% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +2.07% has tacked on 1.0%.

US : U.S.: Nasdaq
$ 1.64
+0.04 +2.50%
Volume: 107,167
Dec. 7, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$13.44 million
Rev. per Employee
US : U.S.: Nasdaq
$ 150.97
+5.70 +3.92%
Volume: 2.61M
Dec. 7, 2021 4:00p
+95.08 +2.07%
Volume: 2.48B
Dec. 7, 2021 5:05p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.